



Hepatocellular Carcinoma (CHALV1): sc-52860

BACKGROUND

Hepatocellular carcinoma (HCC) is a cancer that arises from hepatocytes, the major cell type of the liver. Hepatocellular carcinoma accounts for 80-90% of all liver cancers and occurs more frequently in men than in women. Worldwide, hepatocellular carcinoma is one of the top cancers resulting in death. Cirrhosis, hepatitis B and C infection and exposure to aflatoxins are all risk factors for developing this cancer. Symptoms include abdominal pain, enlarged abdomen, easy bruising and jaundice.

REFERENCES

1. Behrens, H. 1951. A case of hepatocellular carcinoma of the liver with diffuse metastases in the spleen. 87: 18-23.
2. Goldfarb, S. and Zak, F.G. 1962. Role of injury and hyperplasia in the induction of hepatocellular carcinoma. JAMA 178: 729-731.
3. Houstk, J., Masopust, J., Kithier, K. and R-dl, J. 1968. Hepatocellular carcinoma in association with a specific fetal α -1-globulin, fetoprotein. J. Pediatr. 72: 186-193.
4. Smith, J.B. and Blumberg, B.S. 1969. Viral hepatitis, postnecrotic cirrhosis, and hepatocellular carcinoma. Lancet 2: 953.
5. Fox, H., Kondi, A., Linsell, C.A., Parker, A.M. and Sizaret, P. 1970. The α 1-fetoprotein test in hepatocellular carcinoma. Lancet 1: 411.
6. Smith, J.A., Francis, T.I., Edington, G.M. and Williams, A.O. 1972. Immunofluorescent localisation of human α fetoprotein in fetal and neonatal livers and cultured cells from hepatocellular carcinoma. Br. J. Cancer 25: 343-349.
7. Ohtani, M., Ido, K., Kawamoto, C. and Kimura, K. 1989. Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody. Rinsho Byori 37: 405-409.
8. Richart, J., Brunt, E.M. and Di Bisceglie, A.M. 2002. Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining. Dig. Dis. Sci. 47: 2454-2458.
9. Chignard, N., Shang, S., Wang, H., Marrero, J., BrÈchet, C., Hanash, S. and Beretta, L. 2006. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology 130: 2010-2022.

SOURCE

Hepatocellular Carcinoma (CHALV1) is a mouse monoclonal antibody raised against liver carcinoma cells of human origin.

PRODUCT

Each vial contains 100 μ g IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Hepatocellular Carcinoma (CHALV1) is recommended for detection of Hepatocellular Carcinoma of human origin by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with normal human adult tissues and fetal tissues.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.